RxDoctor Payments Data

Erica Altschul, DO

Pulmonary Disease · New York, NYNPI 1073957650

Payments from drug & device makers

$3,276in general payments, 2019–2025

Across 13 payments — averaging $251.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$2K
  • Mylan Specialty L.p.$369
  • Biotronik Inc.$155
  • Sanofi$149
  • AstraZeneca$134
  • Merck$123
  • plus $162 from 2 others

What the payments were for

  • Consulting fees$2,00061%
  • Food & beverage$1,27639%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,276 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$143,011
Medicare patients
347
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan230$2,923,193
WinrevairSotatercept-Csrk66$1,138,847
UptraviSelexipag25$617,221
AdempasRiociguat35$493,152
Orenitram ErTreprostinil Diolamine68$417,172
Ambrisentan41$122,376
Sildenafil Citrate182$53,164
FarxigaDapagliflozin Propanediol63$53,109
JardianceEmpagliflozin45$50,401
EliquisApixaban49$42,722
Tadalafil32$29,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,278
Spiriva RespimatTiotropium Bromide21$11,765
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,094
Breo ElliptaFluticasone/Vilanterol15$7,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$2,184$3,540,414255 claims
MerckWinrevair$123$1,138,84766 claims
Boehringer IngelheimJardiance, Spiriva Respimat$117$62,16766 claims
AstraZenecaFarxiga$134$53,10963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →